Pramlintide acetate in the treatment of type 2 and type 1 diabetes mellitus

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 1, 2007, Pages 9-18

  Edelman, Steven V ^a   Schroeder, Brock E ^b   Frias, Juan P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin; Diabetes mellitus; Hyperglycemia; Insulin; Metabolism; Postprandial; Pramlintide; Type1 diabetes; Type2 diabetes

Indexed keywords

AMYLIN; HUMAN INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LENTE; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAMLINTIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANOREXIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; VOMITING;

EID: 56049119755     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.1.9     Document Type: Article

References (78)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl. 1), S43-S48 (2006).
2. Weyer C, Maggs DG, Young AA et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in Type 1 and Type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr. Pharm. Des. 7(14), 1353-1373 (2001).
3. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258), 405-412 (2000).
4. Diabetes Control and Complications Trial Research Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).
5. United Kingdom Prospective Diabetes Study Group: overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes 44, 1249-1258 (1995).
6. United Kingdom Prospective Diabetes Study Group: intensive blood-gluoose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
7. United Kingdom Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
8. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. 353(25), 2643-2653 (2005).
9. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycernic control? J. Diabetes Complicat. 19(3), 178-181 (2005).
10. DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann. Intern. Med. 131, 281-303 (1999).
11. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 29(Suppl. 1), S4-S42 (2006).
12. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care 19, 744-750 (1996).
13. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with Type 2 diabetes: a preliminary report. Diabetes Care 27, 17-20 (2004).
14. Bonora E, Corrao G, Bagnardi V et al. Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with Type 2 diabetes mellitus. Diabetologia 49, 846-854 (2006).
15. Diabetes Control and Complications Trial Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 11(7), 567-573 (1988).
16. Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with Type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 24(10), 1711-1721 (2001).
17. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat. Endocrinol. 2(1), 33-47 (2003).
18. Triplitt C, DeFronzo RA. Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. Expert Rev. Endocrinol. Metab. 1, 329-341 (2006).
19. Koda JE, Fineman M, Rink TJ et al. Amylin concentrations and glucose control. Lancet 339, 1179-1180 (1992).
20. Koda JE, Fineman MS, Kolterman OG et al. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls [abstract 876]. Diabetes 44(Suppl. 1), A238 (1995).
21. Fineman MS, Giotta MP, Thompson RG et al. Amylin response following Sustacal® ingestion is diminished in Type II diabetic patients treated with insulin [abstract 556]. Diabetologia 39(Suppl. 1), A149 (1996).
22. Weyer C, Maggs DG, Young AA et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in Type 1 and Type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr. Pharm. Des. 7(14), 1353-1373 (2001).
23. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 25(3), 389-397 (1999).
24. Young A, Moore C, Herich J et al. Neuroendocrine actions of amylin. In: The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin. Poyner D, Marshall I, Brain SD (Eds). Landes Bioscience, Georgetown, TX, USA, 91-102 (2000).
25. Beaumont K, Kenney MA, Young AA et al. High affinity amylin binding sites in rat brain. Mol. Pharmacol. 44(3), 493-497 (1993).
26. Riediger T, Rauch M, Jurat G et al. Cellular mechanisms of amylin activating area postrema and subfornical organ neurons [abstract P133]. Soc. Neurosci. Abstr. 25(2), 2140 (1999).
27. Edwards GL, Gedulin BR, Jodka C et al. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin [abstract P133]. Neurogastroenterol. Motil. 10(4), 26 (1998).
28. Riediger T, Zuend D, Becskei C, and Lutz TA. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R114-R122 (2004).
29. Gedulin B, Jodka C, Green D et al. Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon-like-peptide-1 (7-36)-amide (GLP-1) [abstract 584]. Diabetologia 39(Suppl. 1), A154 (1996).
30. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46(1), 67-70 (1997).
31. Gedulin B, Jodka C, Percy A et al. Neutralizing antibody and the antagonist AC187 may inhibit glucagon secretion in rats. Diabetes 40(Suppl. 1), A238 (1997).
32. Silvestre RA, Rodriguez-Gallardo J, Jodka C et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am. J. Physiol. Endocrinol. Metab. 280(3), E443-E449 (2001).
33. Young AA, Gedulin B, Vine W et al. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38(6), 642-648 (1995).
34. 2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45(1), 1-3 (1996).
35. Rushing PA, Hagan MM, Seeley RJ et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology 141(2), 850-853 (2000).
36. Rushing PA. Central amylin signaling and the regulation of energy homeostasis. Curr. Pharm. Des. 9(10), 819-825 (2003).
37. Janes S, Gaeta L, Beaumont K et al. The selection of pramlintide for clinical evaluation. Diabetes 45 (Suppl. 2), A235 (1996).
38. Young AA, Vine W, Gedulin BR et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev. Res. 37(4), 231-248 (1996).
39. SYMLIN® (pramlintide acetate) injection, package insert. Amylin Pharmaceuticals, Inc., San Diego, CA, USA.
40. Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu. Rev. Med. 28, 119-130 (1977).
41. Fineman MS, Koda JE, Shen LZ et al. The human amylin analogue, pramlintide, corrects postprandial hyperglucagonemia in patients with Type 1 diabetes. Metabolism 51(5), 636-641 (2002).
42. Fineman M, Weyer C, Maggs DG et al. The human amylin analogue, pramlintide, reduces postprandial hyperglucagonemia in patients with Type 2 diabetes mellitus. Horm. Metab. Res. 34, 504-508 (2002).
43. Nyholm B, Moller N, Gravholt CH et al. Acute effects of the human amylin analogue AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81(3), 1083-1089 (1996).
44. Amiel SA, Heller SR, Macdonald IA et al. The effect of pramlintide on hormonal, metabolic, or symptomatic responses to insulin-induced hypoglycemia in patients with Type 1 diabetes. Diabetes Obes. Metab. 7, 504-516 (2005).
45. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 24, 371-381 (2001).
46. Nowak TV, Johnson CP, Kalbfleisch JH et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 37, 23-29 (1995).
47. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with Type II diabetes mellitus. Gastroenterology 109, 755-765 (1995).
48. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in Type II diabetic patients. Diabetes Care 19,468-471 (1996).
49. Kong MF, King P, Macdonald IA et al. infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40, 82-88 (1997).
50. Kong MF, Stubbs TA, King P et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41 (5), 577-583 (1998).
51. Chapman I, Parker B, Doran S et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with Type 2 diabetes. Diabetologia 48(5), 838-848 (2005).
52. Kolterman OG, Schwartz S, Corder C et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39(4),492-499 (1996).
53. Nyholm B, Ørskov L, Hove K et al. The amylin analogue pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with Type 1 diabetes mellitus. Metabolism 48(7), 935-941 (1999).
54. Thompson RG, Peterson J, Gottlieb A et al. Effects of pramlimide, an analogue of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 46(4), 632-636 (1997).
55. Thompson RG, Gottlieb A, Organ K et al. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin and c-peptide concentrations in patients with Type II diabetes. Diabet. Med. 14(7), 547-555 (1997).
56. Weyer C, Gottlieb A, Kim D et al. Pramlimide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with Type 1 diabetes: a dose timing study. Diabetes Care 26, 3074-3079 (2003).
57. Maggs DG, Fineman M, Kornstein J et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with Type 2 diabetes: a dose-timing study. Diabetes Metab. Res. Rev. 20 55-60 (2004).
58. Levetan C, Want LL, Weyer C et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglycerides excursions among patients with Type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26(1), 1-8 (2003).
59. Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in Type 1 diabetes. Diabetes Care 25(4), 724-730 (2002).
60. Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic Medicine 21(11), 1204-1212 (2004).
61. Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with Type 2 diabetes: a one-year randomized controlled trial. Diabetes Care 26(3), 784-790 (2003).
62. Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with Type 2 diabetes. Diabetes Technol. Ther. 4(1), 51-61 (2002).
63. Hollander P, Ratner R, Fineman M et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with Type 2 diabetes approaching glycaemic targets. Diabetes Obes. Metab. 5, 408-414 (2003).
64. Edelman S, Garg S, Frias J et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in Type 1 diabetes. Diabetes Care 29 (10), 2189-2195 (2006).
65. Karl D, Philis-Tsimikas A, Darsow T et al. Pramlintide as an adjunct to insulin in patients with Type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions and weight. Diabetes Technol. Ther. (In Press).
66. Guthrie R, Karl DM, Wang Y, Lorenzi G. In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with Type 1 diabetes failing to achieve glycemic targets with insulin therapy [abstract 478-P]. Diabetes 54 (Suppl. 1), A118 (2005).
67. Lush C, Strobel S, Zhang B, Frias J. Ptamlintide, as an adjunct to long-acting insulin, led to improved A1C and body weight in patients with Type 2 diabetes [abstract 521-P]. Diabetes 55, A124 (2006).
68. Frias J, Zhang B, Darsow T. Pramlimide as an adjunct to insulin glargine reduced A1C and body weight in patients with Type 2 diabetes [abstract 472-P]. Diabetes 55, A112 (2006).
69. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19(3), 257-267 (1996).
70. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxdative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 17(3), 189-212 (2001).
71. West IC. Radicals and oxidative stress in diabetes. Diabet. Med. 17(3), 171-180 (2000).
72. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813-820 (2001).
73. Ceriello A, Piconi L, Quagliaro L et al. Effects of pramlintide glucose excursions and measures of oxidative stress in patients with Type 1 diabetes. Diabetes Care 28, 632-637 (2005).
74. Ceriello, A, Lush C, Piconi L et al. Pramlintide reduced markers of oxidative stress in the postprandial period in subjects with Type 2 diabetes [abstract 447-P]. Diabetes 55, A106 (2006).
75. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in Type 1 and Type 2 diabetes: potential benefit of replacing amylin, a second P-cell hormone. Diabetes Technol. Ther. 4, 175-189 (2002).
76. Weyer C, Fineman MS, Strobel S et al. Properties of pramlintide and insulin upon mixing. Am. J. Health Syst. Pharm. 62, 816-822 (2005).
77. Smith SR, Blundell JE, Hompesch M et al. Pramlintide-mediated weight loss in obese subjects is accompanied by sustained reductions in 24-hour caloric intake [abstract 1722-P]. Diabetes 55, A398 (2006).
78. Kruger DF, Gatcomb PM, Owen AK. Clinical implications of arnylin and amylin deficiency. Diabetes Educator 25, 389-397 (1999).